[Relationship between Chemotactic Factor CCL5 and Diabet-associated Diffuse Large B Cell Lymphoma]

Area of Science:

• Oncology
• Immunology
• Endocrinology

Background:

• Diabetes mellitus is associated with an increased risk of certain cancers.
• The role of specific inflammatory mediators in diabetes-associated lymphomagenesis is not fully understood.

Purpose of the Study:

• To investigate the role of the chemotactic factor CCL5 in diffuse large B cell lymphoma (DLBCL) development in the context of diabetes.
• To determine if high glucose levels influence CCL5 expression in DLBCL cells.

Main Methods:

• Cultured normal human B cells and DLBCL cells in vitro, assessing CCL5 mRNA expression via RT-PCR.
• Exposed human and mouse DLBCL cell lines to varying glucose concentrations (5 and 30 mmol/L) to measure CCL5 mRNA levels.
• Established a diabetic mouse model using streptozotocin and injected DLBCL cell lines with varying CCL5 expression levels.
• Analyzed tumor formation rate, time, size, and CCL5 expression in tumor tissues using HE staining and immunohistochemistry.

Main Results:

• CCL5 mRNA expression was significantly higher in DLBCL cells compared to normal B cells and in DLBCL cells cultured in high glucose conditions.
• Diabetic mice injected with high CCL5-expressing DLBCL cells showed a higher tumor formation rate (93.3%) and shorter tumor formation time (7.0 days) compared to those with low CCL5 expression (60%, 9.5 days).
• Tumorigenesis was markedly lower in non-diabetic mice, irrespective of CCL5 expression levels, and CCL5 expression was elevated in tumor tissues of diabetic mice.

Conclusions:

• Elevated blood glucose levels are linked to increased DLBCL risk and enhanced tumor growth.
• The chemotactic factor CCL5 appears to play a significant role in the progression and migration of DLBCL associated with diabetes mellitus.